Healthcare / Medical DevicesTokyo
$388.00
-42.00 (-9.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-1.9B · quality 49.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$46.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-112.9%
↓Gross Margin
63.8%
↑Debt/Equity
1.33
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+66.4%
FCF CAGR
—
FCF margin
-24.9%
FCF / Net income
0.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.93B · net income $-2.50B · FCF $-1.73B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.93B | $6.93B | $4.59B | $2.31B | $1.51B |
| Net Income | $-2.50B | $-2.50B | $-255.5M | $-2.45B | $-1.89B |
| EBITDA | $-2.40B | $-2.40B | $59.1M | $-2.38B | $-1.89B |
| EPS | — | — | -3.49 | -40.64 | -37.20 |
| Gross Margin | 63.8% | 63.8% | 67.3% | 55.7% | 43.9% |
| Operating Margin | -16.7% | -16.7% | -46.1% | -136.5% | -181.7% |
| Net Margin | -36.1% | -36.1% | -5.6% | -105.7% | -125.8% |
| Balance Sheet | |||||
| Debt/Equity | 1.33 | 1.33 | 11.81 | 8.33 | 2.51 |
| Current Ratio | 3.63 | 3.63 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.73B | $-1.73B | $-1.90B | $-4.60B | $-2.92B |
| Returns | |||||
| ROE | -112.9% | -112.9% | -72.3% | -466.1% | -130.0% |
| Valuation | |||||
| EV/EBITDA | — | — | 196.09 | — | — |
| P/B | 17.38 | 17.38 | 24.87 | 17.78 | 11.95 |
| Growth & Yield | |||||
| Revenue Growth | 51.1% | 51.1% | 98.3% | 53.6% | — |
| EPS Growth | — | — | 91.4% | -9.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+181.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.49 → n/d
Residual
+181.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.